
Action Alert
Please consider signing and sharing the Greater Boston PSR open letterto AstraZeneca asking the company to bring Symbicort Turbuhaler to the U.S. market. Signatures can be submitted through this form and both individuals and organizations can sign on. Sign by July 29th.
This dry powder form of Symbicort (budesonide-formoterol) is the formulation used in many of the asthma trials, and is readily available in Canada, UK, much of Europe, China, and other Asian countries – but not the U.S.
As background, the propellants in pressurized metered dose inhalers (MDIs) are potent greenhouse gases that are responsible for roughly 4% of the National Health System's greenhouse gas emissions. In 2020, the greenhouse gas emissions from metered dose inhaler use in the US were the equivalent of driving 500,000 cars for a year. Switching from pressurized MDIs to dry powder inhalers, when appropriate, can significantly reduce these emissions. The specific propellant in Symbicort MDI (HFA 227ea) has 3,350 times the global warming potential over 100 years as compared to that of CO2. It is critical that patients, in the U.S., have access to low emissions dry powder inhalers like Symbicort Turbuhaler, especially as budesonide-formoterol is an important tool included in global and national asthma management guidelines.
Sign on Here
What We Are Reading & Listening to This Week
Join Us
July 9th: 5:30 pm – 6:30 pm AzNA Climate Change & Health Workgroup June. Zoom Link
July 11th: 12:00 pm (AZ) ANHE Policy & Advocacy Forum: The Lead & Copper Rule: Opportunities for Nursing Action Register
September 10th: 12:00 pm – 2:00 pm Arizona Health Professionals for Climate Action Annual Virtual Summit Zoom Link
Thank you for joining us in making a healthier planet today!